Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, 90 count bottles, Manufactured by: Auro...

FDA Recall #D-0156-2025 — Class II — December 6, 2024

Recall #D-0156-2025 Date: December 6, 2024 Classification: Class II Status: Ongoing

Product Description

Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, 90 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-414-05

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

Recalling Firm

Amerisource Health Services LLC — Columbus, OH

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

13,678 bottles

Distribution

Nationwide in the USA

Code Information

Lot DT3023030A Exp 2/28/2025

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated